The regulators have accepted the firm’s filings for investigational oral and once-daily siponimod to treat secondary progressive multiple sclerosis (SPMS) in adults. Siponimod is an investigational and selective
The post FDA and EMA accept Novartis’ filings for MS drug Siponimod appeared first on Pharma Business review.
Original Article: FDA and EMA accept Novartis’ filings for MS drug Siponimod